Skip to content

US · ADCT · BIOTECHNOLOGY

ADC Therapeutics S.A. (ADCT) intrinsic value and stock valuation

$1.28as of 2026-11-21 · Mkt cap 143.73M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ADC Therapeutics S.A. DCF and intrinsic value

InvestorsCraft values ADCT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ADCT’s statements →

ADC Therapeutics S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Epalinges, VD 1066 adctherapeutics.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$81.4M
20172025
Net income
-$-142.62M
20172025
Free cash flow
-$-141.44M
20172025
Total equity
-$-185.83M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$81.4M$70.8M$69.6M$209.9M$33.9M
Operating income-$-108.38M-$-130.65M-$-165.99M-$-123.34M-$-261.72M
Net income-$-142.62M-$-157.85M-$-240.05M-$-157.13M-$-230.03M
EPSd-$-1.12M-$-1.62M-$-2.94M-$-2.01M-$-3M
Operating cash flow-$-141.17M-$-123.83M-$-118.69M-$-138.31M-$-233.38M
Capital expenditure-$-260K-$-870K-$-3.22M-$-690K-$-6.38M
Free cash flow-$-141.44M-$-124.7M-$-121.9M-$-139M-$-239.75M
Total assets$323.2M$322M$354.8M$490.9M$618M
Total debt$439M$123M$124.4M$129.9M$139.7M
Net debt$177.7M-$-127.87M-$-154.22M-$-196.59M-$-326.85M
Total equity-$-185.83M-$-202.64M-$-148.25M$79.5M$166.1M
Cash and short-term investments$261.3M$250.9M$278.6M$326.4M$466.5M
Income statement
20252024202320222021
Revenue$81.4M$70.8M$69.6M$209.9M$33.9M
Cost of revenue$7.67M$5.95M$2.53M$3.3M$1.39M
Gross profit$73.7M$64.9M$67M$206.6M$32.5M
Research and development expenses$104M$109.6M$127.1M$186.5M$158M
Selling, general and administrative expenses-$-6.82M$85.9M$105.9M$143.5M$136.2M
Other expenses$84.9M$0.00$0.00$0.00$0.00
Operating expenses$182.1M$195.5M$233M$330M$294.2M
Cost and expenses$189.7M$201.5M$235.5M$333.3M$295.6M
Interest income$8.81M$12.3M$10.5M$2.57M$70K
Interest expense$51.6M$50.2M$46.3M$36.7M$18.3M
Depreciation and amortization$1.88M$3.28M$3.27M$2.39M$2.63M
Ebitda-$-89.27M-$-102.65M-$-145.83M-$-107.7M-$-230.53M
Operating income-$-108.38M-$-130.65M-$-165.99M-$-123.34M-$-261.72M
Total other income/expenses, net-$-34.4M-$-27.03M-$-34.96M-$-33.56M$10.2M
Income before tax-$-142.78M-$-157.68M-$-200.95M-$-156.9M-$-251.5M
Income tax expense-$-160K$170K$39.1M$230K-$-21.48M
Net income-$-142.62M-$-157.85M-$-240.05M-$-157.13M-$-230.03M
Weighted average shares outstanding$127.1M$97.2M$81.7M$78.2M$76.8M
Weighted average diluted shares outstanding$127.1M$97.2M$81.7M$78.2M$76.8M
Balance sheet
20252024202320222021
Cash and short-term investments$261.3M$250.9M$278.6M$326.4M$466.5M
Net receivables$29.1M$20.3M$25.2M$73M$31.1M
Inventory$4.18M$18.4M$16.2M$12.1M$11.1M
Total current assets$306.3M$307.4M$336.3M$435M$525.2M
Property, plant and equipment, net$1.3M$13.4M$16.1M$10.3M$11.2M
Goodwill and intangible assets$0.00$0.00$0.00$14.4M$13.6M
Long-term investments$0.00$0.00$1.65M$7.61M$41.2M
Total non-current assets$16.8M$14.6M$18.5M$55.9M$92.8M
Total assets$323.2M$322M$354.8M$490.9M$618M
Accounts payable$9.18M$18M$15.6M$12.4M$12.1M
Short-term debt$3M$1.37M$1.47M$13.6M$7.6M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$70.2M$80.5M$67.7M$81.9M$73.9M
Long-term debt$437.1M$121.6M$122.9M$116.3M$132.1M
Deferred revenue, non-current$0.00$320.1M$0.00$23.5M$23.5M
Total non-current liabilities$438.8M$444.2M$435.4M$329.5M$378M
Capital lease obligations$1.03M$9.37M$11.7M$7.66M$8.02M
Total liabilities$509M$524.6M$503M$411.4M$451.9M
Common stock$11.1M$8.43M$7.31M$7.31M$6.45M
Retained earnings-$-1.64B-$-1.49B-$-1.34B-$-1.1B-$-924.88M
Accumulated other comprehensive income (loss)-$-520K-$-1.42M-$-90K$1.82M$102.8M
Total equity-$-185.83M-$-202.64M-$-148.25M$79.5M$166.1M
Total investments$0.00$0.00$1.65M$7.61M$41.2M
Total debt$439M$123M$124.4M$129.9M$139.7M
Net debt$177.7M-$-127.87M-$-154.22M-$-196.59M-$-326.85M
Cash flow statement
20252024202320222021
Net income-$-142.62M-$-157.85M-$-240.05M-$-157.13M-$-230.03M
Depreciation and amortization$1.88M$3.28M$3.27M$5.74M$2.63M
Stock-based compensation$6.91M$6.57M$13.5M$50.6M$60.5M
Change in working capital-$-25.36M$3.83M$44.3M-$-49.03M-$-15.71M
Accounts receivable-$-8.79M$4.77M$47.8M-$-42.75M-$-30.22M
Inventory-$-2.38M-$-3.73M-$-5.71M-$-9.65M-$-3.02M
Accounts payable-$-9.04M$2.46M$3.17M$310K$6.8M
Net cash provided by operating activities-$-141.17M-$-123.83M-$-118.69M-$-138.31M-$-233.38M
Investments in property, plant and equipment-$-260K-$-870K-$-3.22M-$-690K-$-3.43M
Acquisitions, net$660K$0.00$0.00$0.00$0.00
Net cash used for investing activities$400K-$-870K-$-3.22M-$-690K-$-6.67M
Common stock issued$152.5M$60.5M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00-$-1.31M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$150.9M$97.1M$73.9M-$-900K$267.4M
Net change in cash$10.5M-$-27.73M-$-47.84M-$-140.1M$27.4M
Cash at end of period$261.3M$250.9M$278.6M$326.4M$466.5M
Operating cash flow-$-141.17M-$-123.83M-$-118.69M-$-138.31M-$-233.38M
Capital expenditure-$-260K-$-870K-$-3.22M-$-690K-$-6.38M
Free cash flow-$-141.44M-$-124.7M-$-121.9M-$-139M-$-239.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ADC Therapeutics S.A.

        ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.

        CEO
        Ameet Mallik
        Employees
        191
        Beta
        1.88

        Explore

        Frequently asked questions

        What is the intrinsic value of ADC Therapeutics S.A. (ADCT)?

        ADC Therapeutics S.A. (ADCT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ADCT undervalued?

        ADCT trades at a price of $1.28 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.